As of Mar 31, 2025
VanEck Pharmaceutical ETF (NASDAQ: PPH)
Ticker | Name | Share % | |
---|---|---|---|
LLY | Eli Lilly & Co | 11.60% | |
CO | Novo Nordisk A/S ADR | 6.35% | |
JNJ | Johnson & Johnson | 6.56% | |
MRK | Merck & Co Inc | 4.75% | |
ABBV | Abbvie Inc | 6.54% | |
LN | Astrazeneca Plc, ADR | 5.02% | |
GVMXX | State Street Navigator Securities Lending Government Money Market Portfolio | 4.71% | |
SM | Novartis Ag | 5.30% | |
COR | Cencora Inc | 5.26% | |
MCK | Mckesson Corp | 5.17% | |
PA | Sanofi Sa | 4.86% |
The PPH ETF is currently trading at $83.17, which represents a -0.13% change. Over the past 52 weeks, the ETF has traded as high as $99.51 and as low as $77.67.
The expense ratio of PPH is 0.36%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for PPH is 606.50M. This represents the total market value of the assets managed by the ETF.
PPH follows a Large Cap Value investment style.
The top holdings of PPH include: LLY (11.6%), CO (6.35%), JNJ (6.56%), MRK (4.75%), ABBV (6.54%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for PPH is currently not available.